Editas Medicine to Participate in Investor Conferences in October

CAMBRIDGE, Mass., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. EDIT, a leading genome editing company, today announced that management will participate in two upcoming investor conferences in New York in October.  Details are as follows:

Chardan Gene Therapy Conference
Tuesday, October 10

• Manufacturing Panel | 12:15 p.m. ET
• Fireside Chat | 3:45 p.m. ET

Jefferies Gene Technology Investor Summit
Thursday, October 12

• Presentation | 1:20 p.m. ET

A live webcast of the events will be available on the Investors & Media section of the Editas Medicine website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the events.
                                         
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes.  The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Media Contact
Cristi Barnett

Editas Medicine, Inc.
(617) 401-0113
cristi.barnett@editasmed.com

Investor Contact
Mark Mullikin
Editas Medicine, Inc.
(617) 401-9083
mark.mullikin@editasmed.com